Cinven to Acquire Theramex in €2.6 Billion Deal

• Cinven is acquiring Theramex, a specialty pharmaceutical company focused on menopause treatments.
• The acquisition deal is valued at €2.6 billion ($3.0 billion).
• Cinven is securing debt financing of approximately €1.5 billion ($1.7 billion) to fund the acquisition.
• Theramex specializes in treatments for menopause and related conditions.
• The deal is expected to close following necessary regulatory approvals.